{"title":"HPV E6诱导ADAM10表达升高对宫颈癌预后的影响","authors":"Xuewang Guo, Yu Dou, Shuiqingqing Liu, Yue Du, Ruimeng Guo, Yingying Yue, Yu Xu, Xueying Liu, Yanying Xu","doi":"10.1089/gtmb.2022.0170","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Objective:</i></b> To explore the abnormal expression of <i>ADAM10</i>, its cause, and its clinical value in the prognosis of cervical lesions. <b><i>Methods:</i></b> The abnormal expression of <i>ADAM10</i> was explored using the Gene Expression Profiling Interactive Analysis database, and the abnormal expression in cervical lesions was verified using immunohistochemistry (IHC). The transfection effect of shRNA was evaluated using real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The expression of <i>ADAM10</i> in cells was analyzed using western blotting. <b><i>Results:</i></b> <i>ADAM10</i> was highly expressed in multiple cancers. As the disease progressed, the expression of <i>ADAM10</i> gradually increased (<i>p</i> < 0.05). Patients with higher expression of <i>ADAM10</i> had poorer survival outcomes than those with lower expression levels (<i>p</i> < 0.05). The expression levels of <i>ADAM10</i> decreased after expression levels of E6 was inhibited. <b><i>Conclusion:</i></b> <i>ADAM10</i> is highly expressed in cervical cancer; the higher the expression levels, the worse the survival outcome. HPV E6 is the critical driver of the elevated expression of <i>ADAM10</i> in cervical cancer.</p>","PeriodicalId":12603,"journal":{"name":"Genetic testing and molecular biomarkers","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Elevated Expression of <i>ADAM10</i> Induced by HPV E6 Influences the Prognosis of Cervical Cancer.\",\"authors\":\"Xuewang Guo, Yu Dou, Shuiqingqing Liu, Yue Du, Ruimeng Guo, Yingying Yue, Yu Xu, Xueying Liu, Yanying Xu\",\"doi\":\"10.1089/gtmb.2022.0170\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b><i>Objective:</i></b> To explore the abnormal expression of <i>ADAM10</i>, its cause, and its clinical value in the prognosis of cervical lesions. <b><i>Methods:</i></b> The abnormal expression of <i>ADAM10</i> was explored using the Gene Expression Profiling Interactive Analysis database, and the abnormal expression in cervical lesions was verified using immunohistochemistry (IHC). The transfection effect of shRNA was evaluated using real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The expression of <i>ADAM10</i> in cells was analyzed using western blotting. <b><i>Results:</i></b> <i>ADAM10</i> was highly expressed in multiple cancers. As the disease progressed, the expression of <i>ADAM10</i> gradually increased (<i>p</i> < 0.05). Patients with higher expression of <i>ADAM10</i> had poorer survival outcomes than those with lower expression levels (<i>p</i> < 0.05). The expression levels of <i>ADAM10</i> decreased after expression levels of E6 was inhibited. <b><i>Conclusion:</i></b> <i>ADAM10</i> is highly expressed in cervical cancer; the higher the expression levels, the worse the survival outcome. HPV E6 is the critical driver of the elevated expression of <i>ADAM10</i> in cervical cancer.</p>\",\"PeriodicalId\":12603,\"journal\":{\"name\":\"Genetic testing and molecular biomarkers\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2023-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Genetic testing and molecular biomarkers\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1089/gtmb.2022.0170\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"GENETICS & HEREDITY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genetic testing and molecular biomarkers","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1089/gtmb.2022.0170","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
Elevated Expression of ADAM10 Induced by HPV E6 Influences the Prognosis of Cervical Cancer.
Objective: To explore the abnormal expression of ADAM10, its cause, and its clinical value in the prognosis of cervical lesions. Methods: The abnormal expression of ADAM10 was explored using the Gene Expression Profiling Interactive Analysis database, and the abnormal expression in cervical lesions was verified using immunohistochemistry (IHC). The transfection effect of shRNA was evaluated using real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The expression of ADAM10 in cells was analyzed using western blotting. Results:ADAM10 was highly expressed in multiple cancers. As the disease progressed, the expression of ADAM10 gradually increased (p < 0.05). Patients with higher expression of ADAM10 had poorer survival outcomes than those with lower expression levels (p < 0.05). The expression levels of ADAM10 decreased after expression levels of E6 was inhibited. Conclusion:ADAM10 is highly expressed in cervical cancer; the higher the expression levels, the worse the survival outcome. HPV E6 is the critical driver of the elevated expression of ADAM10 in cervical cancer.
期刊介绍:
Genetic Testing and Molecular Biomarkers is the leading peer-reviewed journal covering all aspects of human genetic testing including molecular biomarkers. The Journal provides a forum for the development of new technology; the application of testing to decision making in an increasingly varied set of clinical situations; ethical, legal, social, and economic aspects of genetic testing; and issues concerning effective genetic counseling. This is the definitive resource for researchers, clinicians, and scientists who develop, perform, and interpret genetic tests and their results.
Genetic Testing and Molecular Biomarkers coverage includes:
-Diagnosis across the life span-
Risk assessment-
Carrier detection in individuals, couples, and populations-
Novel methods and new instrumentation for genetic testing-
Results of molecular, biochemical, and cytogenetic testing-
Genetic counseling